The data are available from the Korean National Health Insurance Service (NHIS); however, the access to data is limited to researchers who meet the required criteria. Any researchers who propose a study subject and plans with standardized proposal form can access the raw data after being approved by NHIS review committee of research support. Detailed process and a provision guide is now available at (<http://nhiss.nhis.or.kr/bd/ab/bdaba000eng.do>).

Introduction {#sec005}
============

Autoimmune hepatitis (AIH) is a rare, chronic liver disease characterized by the presence of auto-antibodies, hypergammaglobulinemia, and interface hepatitis on histological examination. AIH, unless treated properly, can progress to cirrhosis or hepatic failure. Nonetheless, the epidemiology, treatment pattern, and disease burden of AIH are difficult to determine because of diverse clinical presentations and low prevalence.

The disease prevalence and incidence of AIH differ by race and ethnicity. Prevalence estimates range widely from 4 to 42.9 cases per 100,000 persons \[[@pone.0182391.ref001]--[@pone.0182391.ref011]\], and reported annual incidences range from 0.67 to 2.23 cases per 100,000 persons.\[[@pone.0182391.ref001], [@pone.0182391.ref004], [@pone.0182391.ref006], [@pone.0182391.ref008]--[@pone.0182391.ref014]\] The variable results may be attributed to differences in genetics, environmental factors, and study population or design, and these heterogeneous factors make it challenging to understand the global epidemiology and disease burden of AIH.

A comprehensive study on the nationwide epidemiology and direct medical costs of AIH may be able to overcome selection biases related to patients and organizations when based on a population-based administrative database. This study used a claims data base from the Korean National Health Insurance (NHI) system, which is a mandatory nationwide insurance system operated by the government. This data set includes almost all of the population's inpatient and outpatient healthcare utilization data (96.6% in 2010) and contains all medical and prescription drug-claim records. In addition, NHI has an established registry program for rare intractable diseases (RID), which includes AIH or primary biliary cirrhosis (PBC), for copayment reduction since 2009. To be registered to this RID system, physicians must confirm the specific diagnosis by checking the listed diagnostic criteria and then register their patients. The aim of this study was to investigate the nationwide, population-based epidemiology, clinical features (such as complications or comorbidities), and disease burden of AIH in South Korea using these two big databases.

Patients and methods {#sec006}
====================

Data source {#sec007}
-----------

The present study used the nationwide NHI claims database and RID database, which contain inpatient and outpatient healthcare utilization information such as patients' demographics, date of admission and discharge, date of visit, diagnostic procedures such as laboratory tests or imaging studies, surgical procedures, prescription history, principal diagnoses or comorbidities based on the International Classification of Disease, 10^th^ Revision (ICD-10), and RID registry information. Patients with RIDs become eligible for copayment reduction after their diagnoses are confirmed by a physician on the basis of the RID-defined diagnostic criteria provided by the NHI. Diagnoses are reviewed by the corresponding healthcare institution before being submitted to the NHI. All personal identities were encrypted and all data was analyzed anonymously. The cases of death were investigated from the data of Statistics Korea. This study was approved by the Institutional Review Board of the National Cancer Center (NCC2014-0182).

Study population {#sec008}
----------------

Patients with the disease code of AIH (K75.4) between January 2009 and December 2013 were retrieved from the claims data of NHI and were matched with the RID registry program. In the RID registry program, AIH was identified through a clinical diagnosis based on the results of auto-antibodies, immunoglobulin G, or histological examination and differential diagnosis from other liver diseases such as viral hepatitis. A prevalent case was defined as a case with AIH as the primary or secondary diagnosis of the year along with records of visits, hospitalizations, or surgeries in the claims database of NHI. An incident case was defined as a newly registered one without any claims data for AIH during the washout period to exclude prevalent cases. A 2-year washout period (2009--2010) was used in this study; therefore, new cases from 2011 were those that had no claims data for AIH in 2009 and 2010.

Statistical analyses {#sec009}
--------------------

This study calculated the crude and adjusted prevalence of AIH in Korea during 2009 to 2013 using the number of AIH cases in the corresponding year divided by the population and by age- and gender-specific populations of the standard population. The standard population for the age- and gender adjusted prevalence rates was the registered population in 2010 by the Ministry of Government Administration and Home Affairs of the Republic of Korea.\[[@pone.0182391.ref015]\] The incidence rate was calculated by newly registered cases divided by the registered population. Cases of death from Statistics Korea were used for the case-fatality rate. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA), and a p-value \<0.05 was considered to indicate a statistically significant difference.

Results {#sec010}
=======

Prevalence and incidence of AIH in South Korea {#sec011}
----------------------------------------------

From 2009 to 2013, a total of 4,085 AIH cases were registered after excluding duplicate cases. Among them, 3,493 were females (85.5%) and 592 were males (14.5%) with a female-to-male ratio of 6.4. The median case age was 56 years (56 for females and 55 for males), and the mean age was 54.9 years (55.1 for women and 53.2 for men).

The average age-adjusted prevalence rate of AIH was 4.82/100,000 persons (gender-adjusted: 8.35 in females and 1.30 in males) during 2009--2013 ([Table 1](#pone.0182391.t001){ref-type="table"}). The peak prevalence was in ages 60--69 (15.24/100,000, [Fig 1](#pone.0182391.g001){ref-type="fig"}) and was ages 60--69 for females (25.53/100,000) and 70--79 for males (4.62/100,000).

10.1371/journal.pone.0182391.t001

###### Crude and adjusted prevalence and incidence rates per 100,000 of AIH in South Korea.

![](pone.0182391.t001){#pone.0182391.t001g}

                   Standard population[\*](#t001fn001){ref-type="table-fn"}   Total number of cases   2009    2010    2011    2012    2013    Average, annual, adjusted rate
  ---------------- ---------------------------------------------------------- ----------------------- ------- ------- ------- ------- ------- -------------------------------------------
  **Prevalence**                                                                                                                              
  Gender                                                                                                                                      
   Male            25,035,384                                                 1686                    1.12    1.13    1.28    1.47    1.51    1.30[†](#t001fn002){ref-type="table-fn"}
   Female          24,973,069                                                 10,761                  6.69    7.26    8.42    9.36    10.02   8.35[†](#t001fn002){ref-type="table-fn"}
  Age (years)                                                                                                                                 
   0--9            4757524                                                    18                      0.12    0.04    0.09    0.09    0.04    0.08[‡](#t001fn003){ref-type="table-fn"}
   10--19          6826875                                                    154                     0.51    0.45    0.43    0.45    0.48    0.47[‡](#t001fn003){ref-type="table-fn"}
   20--29          6,826,755                                                  422                     1.15    1.20    1.41    1.28    1.24    1.25[‡](#t001fn003){ref-type="table-fn"}
   30--39          8,278,025                                                  842                     1.80    1.74    2.23    2.30    2.25    2.06[‡](#t001fn003){ref-type="table-fn"}
   40--49          8,701,782                                                  2,021                   3.84    4.26    4.67    5.09    5.27    4.63[‡](#t001fn003){ref-type="table-fn"}
   50--59          6,945,354                                                  3,689                   8.69    8.68    10.00   11.26   11.65   10.06[‡](#t001fn003){ref-type="table-fn"}
   60--69          4,137,957                                                  3,210                   11.87   13.22   15.03   17.06   19.04   15.24[‡](#t001fn003){ref-type="table-fn"}
   70--79          2,595,847                                                  1,810                   8.63    10.67   12.89   15.54   17.14   12.97[‡](#t001fn003){ref-type="table-fn"}
   80+             938,334                                                    281                     3.31    4.05    5.41    6.43    7.91    5.42[‡](#t001fn003){ref-type="table-fn"}
  Total            50,008,453                                                 12,447                  3.90    4.19    4.84    5.41    5.76    4.82[§](#t001fn004){ref-type="table-fn"}
  **Incidence**                                                                                                                               
  Gender                                                                                                                                      
   Male            25,035,384                                                 249                                     0.32    0.36    0.27    0.31[†](#t001fn002){ref-type="table-fn"}
   Female          24,973,069                                                 1,438                                   1.91    1.87    1.70    1.83[†](#t001fn002){ref-type="table-fn"}
  Age (years)                                                                                                                                 
   0--9            4757524                                                    5                                       0.04    0.06    0.00    0.04[‡](#t001fn003){ref-type="table-fn"}
   10--19          6826875                                                    18                                      0.09    0.11    0.08    0.09[‡](#t001fn003){ref-type="table-fn"}
   20--29          6,826,755                                                  52                                      0.42    0.15    0.22    0.26[‡](#t001fn003){ref-type="table-fn"}
   30--39          8,278,025                                                  135                                     0.61    0.58    0.48    0.56[‡](#t001fn003){ref-type="table-fn"}
   40--49          8,701,782                                                  272                                     1.14    0.99    0.99    1.04[‡](#t001fn003){ref-type="table-fn"}
   50--59          6,945,354                                                  533                                     2.30    2.72    1.97    2.33[‡](#t001fn003){ref-type="table-fn"}
   60--69          4,137,957                                                  396                                     2.82    3.42    3.06    3.10[‡](#t001fn003){ref-type="table-fn"}
   70--79          2,595,847                                                  229                                     3.04    2.37    2.56    2.66[‡](#t001fn003){ref-type="table-fn"}
   80+             938,334                                                    47                                      1.50    1.21    1.65    1.46[‡](#t001fn003){ref-type="table-fn"}
  Total            50,008,453                                                 1,687                                   1.11    1.12    0.98    1.07[§](#t001fn004){ref-type="table-fn"}

\*Standard population, inhabitants in 2010

^†^Adjusted for age

^‡^Adjusted for gender

^§^Adjusted for age and gender

![(A) Average annual gender-adjusted incidence rate per hundred thousand population and incident cases (2009--2013) of AIH by age in South Korea. (B) Average annual gender-adjusted prevalence rate per hundred thousand population and prevalent cases (2009--2013) of AIH by age in South Korea.](pone.0182391.g001){#pone.0182391.g001}

To determine the incidence accurately, the washout period was set for 2 years, and the incidence rate was calculated from 2011 to 2013. The overall age-adjusted AIH incidence rate during 2011--2013 was 1.07/100,000/year (gender-adjusted: 1.83 in females and 0.31 in males). Age-specific incidence rate was highest in ages 60--69 (3.10/100,000/year). By gender, it was the highest in ages 60--69 for women (5.07/100,000/year) and in ages over 80 (1.60/100,000/year) for men.

Complications and case fatality of AIH in South Korea {#sec012}
-----------------------------------------------------

ICD-10 code identified ascites was present in 1.4% of patients with AIH between 2009 and 2013, while diuretics (spironolactone) was prescribed in 5.8% of those with AIH ([Table 2](#pone.0182391.t002){ref-type="table"}). ICD-10 code identified variceal bleeding was reported in 1.3% of patients with AIH. Endoscopic intervention for variceal bleeding was performed in 1.9% of patients, vasoactive medications such as terlipressin, somatostatin, or octreotide were given in 2.1%, and propranolol in 5.6% of patients during the 5 year study period. ICD-10 code identified hepatic encephalopathy was recorded in 2.2% of patients, and lactulose was prescribed in 12.3%. Hepatocellular carcinoma was diagnosed in 31 patients (0.8%). The median age of the 31 patients was 65 (range, 60--69), and 77.4% were females. Among them, 3 and 9 underwent surgical resection and local ablation, respectively. Liver transplantation was performed in 46 patients, and their median age was 53.5 (range, 43--61) and 89.1% were females.

10.1371/journal.pone.0182391.t002

###### Proportion of AIH patients with complications or comorbidities from 2009 to 2013.
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  Complications or comorbidities                                  Male (n = 592, 14.5%)   Female (n = 3493, 85.5%)                                     
  --------------------------------------------------------------- ----------------------- -------------------------- ---------- ---------- ----------- -----------
  **Complications**                                                                                                                                    
  Ascites[\*](#t002fn001){ref-type="table-fn"}                    0(0.0)                  2(0.7)                     8(3.3)     1(0.6)     19(1.0)     26(1.9)
   Prescription of spironolactone                                 2(3.1)                  19(6.6)                    9(3.8)     5(3.1)     114(5.8)    89(6.6)
   Prescription of furosemide                                     2(3.1)                  26(9.0)                    45(18.8)   20(12.3)   184(9.3)    234(17.3)
  Variceal bleeding[\*](#t002fn001){ref-type="table-fn"}          1(1.5)                  3(1.0)                     1(0.4)     2(1.2)     25(1.3)     21(1.5)
   Endoscopic intervention                                        0(0.0)                  4(1.4)                     1(0.4)     4(2.5)     33(1.7)     36(2.7)
   TIPS[†](#t002fn002){ref-type="table-fn"}                       0(0.0)                  1(0.3)                     0(0.0)     0(0.0)     0(0.0)      1(0.1)
   Prescription of vasoactive agents                              1(1.5)                  8(2.8)                     1(0.4)     4(2.5)     35(1.8)     38(2.8)
   Prescription of propranolol                                    2(3.1)                  12(4.2)                    14(5.9)    10(6.1)    92(4.7)     97(7.2)
  Hepatic encephalopathy[\*](#t002fn001){ref-type="table-fn"}     0(0.0)                  4(1.4)                     8(3.3)     5(3.1)     37(1.9)     34(2.5)
   Prescription of lactulose                                      4(6.2)                  25(8.7)                    30(12.6)   14(8.6)    219(11.1)   211(15.6)
  Liver cirrhosis[\*](#t002fn001){ref-type="table-fn"}            9(13.8)                 69(24.0)                   73(3.1)    31(19.0)   545(27.6)   596(44.0)
  Hepatocellular carcinoma[\*](#t002fn001){ref-type="table-fn"}   0(0.0)                  1(0.3)                     6(2.5)     0(0.0)     10(0.5)     14(1)
   Liver resection                                                0(0.0)                  2(0.7)                     0(0.0)     0(0.0)     0(0.0)      1(0.1)
   Local ablation                                                 0(0.0)                  0(0.0)                     1(0.4)     0(0.0)     3(0.2)      5(0.4)
   Transarterial chemoembolization                                0(0.0)                  1(0.3)                     2(0.8)     1(0.6)     6(0.3)      8(0.6)
  Liver transplantation[\*](#t002fn001){ref-type="table-fn"}      1(1.5)                  2(0.7)                     2(0.8)     5(3.1)     24(1.2)     12(0.9)
  **Comorbidities**                                                                                                                                    
  Thyroid disease                                                                                                                                      
   Hypothyroidism                                                 2(3.1)                  4(1.4)                     2(0.8)     3(1.8)     68(3.4)     33(2.4)
   Hyperthyroidism                                                0(0.0)                  3(1)                       0(0.0)     3(1.8)     22(1.1)     9(0.7)
   Thyroiditis                                                    0(0.0)                  3(1)                       0(0.0)     1(0.6)     22(1.1)     10(0.7)
   Prescription of thyroid hormone                                0(0.0)                  13(4.5)                    11(4.6)    2(1.2)     69(3.5)     53(3.9)
   Prescription of anti-thyroid drugs                             0(0.0)                  1(0.3)                     0(0.0)     3(1.8)     8(0.4)      3(0.2)
  Autoimmune disease                                                                                                                                   
   Primary biliary cirrhosis                                      1(1.5)                  20(6.9)                    13(5.4)    4(2.5)     173(8.8)    91(6.7)
   Systemic lupus erythematosus                                   3(4.6)                  2(0.7)                     0(0.0)     6(3.7)     46(2.3)     9(0.7)
   Systemic sclerosis                                             0(0.0)                  0(0.0)                     2(0.8)     0(0.0)     5(0.3)      1(0.1)
   Rheumatoid arthritis                                           0(0.0)                  1(0.3)                     0(0.0)     0(0.0)     4(0.2)      6(0.4)
  Dyslipidemia                                                    1(1.5)                  25(8.7)                    38(15.9)   14(8.6)    165(8.4)    228(16.8)
   Prescription of statin                                         3(4.6)                  40(13.9)                   26(10.9)   9(5.5)     288(14.6)   226(16.7)
  Osteoporosis                                                    0(0.0)                  0(0.0)                     0(0.0)     1(0.6)     4(0.2)      4(0.3)
   Prescription of bisphosphonate                                 0(0.0)                  0(0.0)                     13(5.4)    0(0.0)     38(1.9)     100(7.4)

\*Complications or comorbidities were identified with ICD-10 codes verified by physicians.

^†^TIPS denotes transjugular intrahepatic portosystemic shunt surgery.

N = 4085

During the 5 years of study, 271 of 4,085 patients died. The overall case-fatality ratio was 6.63% (6.38% for females and 8.11% for males). The average annual case fatality ratio was 2.18% (2.07% for females and 2.85% for males) as shown in [Table 3](#pone.0182391.t003){ref-type="table"}.

10.1371/journal.pone.0182391.t003

###### Case-fatality ratio (CFR, %)[\*](#t003fn001){ref-type="table-fn"} for patients with AIH by gender and year in South Korea.
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  ----------------------------------------------------------------------------------------------------------------------------------
               2009\        2010\        2011\        2012\        2013\        Five year CFR[†](#t003fn002){ref-type="table-fn"}\
               (n = 1899)   (n = 2095)   (n = 2487)   (n = 2853)   (n = 3113)   (n = 4085)
  ------------ ------------ ------------ ------------ ------------ ------------ ----------------------------------------------------
  Number (%)                                                                    

   Female      21 (1.29)    40 (2.21)    53 (2.45)    54 (2.19)    55 (2.04)    223 (2.07)

   Male        5 (1.82)     6 (2.13)     9 (2.74)     15 (3.85)    13 (3.16)    48 (2.85)

   Total       26 (1.37)    46 (2.20)    62 (2.49)    69 (2.42)    68 (2.18)    271 (2.18)
  ----------------------------------------------------------------------------------------------------------------------------------

\* The case-fatality ratio was calculated by dividing the number of death cases in the corresponding year by the treated AIH cases.

^†^During 5 years (2009--2013), 271 of 4085 patients died, resulting in an overall case-fatality ratio of 2.18%

Diagnosis and treatment for AIH in Korea {#sec013}
----------------------------------------

Of the 507 patients newly diagnosed with AIH in 2013, liver biopsy was performed in 54.2% of them. Tests for anti-nuclear antibody, anti-smooth muscle antibody, anti-mitochondrial antibody, and anti-liver kidney microsome type 1 antibody were done in 93.9%, 81.7%, 88.4% and 67.5% of patients, respectively. Among 3,113 prevalent AIH cases in year 2013, corticosteroid and azathioprine were prescribed in 44.1% and 38.0%, respectively.

Comorbidities in patients with AIH {#sec014}
----------------------------------

The most frequently encountered comorbid disease identified by ICD-10 codes and prescribed drugs was dyslipidemia (11.5%), which was followed by thyroid diseases ([Table 2](#pone.0182391.t002){ref-type="table"}). Prevalence of comorbid PBC was found to be 7.4% in patients with AIH, suggesting an overlap syndrome. Systemic lupus erythematosus was also identified in 1.6% of AIH patients. Osteoporosis estimated by the prescription of bisphosphonate was present in 3.7% of patients.

Out of 302 patients diagnosed with AIH and PBC, 88.7% were females, and the median age was 54 ([Table 4](#pone.0182391.t004){ref-type="table"}). Ascites and variceal bleeding identified by the ICD-10 disease code were more frequently found in patients with AIH-PBC compared to those diagnosed with AIH only. Liver transplantation was also performed more often in patients with AIH-PBC. However, reported frequencies of other comorbidities or HCC were comparable ([Table 4](#pone.0182391.t004){ref-type="table"}).

10.1371/journal.pone.0182391.t004

###### Comparison between patients with only AIH and AIH-PBC.

![](pone.0182391.t004){#pone.0182391.t004g}

  ------------------------------------------------------------------------------------------------------------------
                                                                  Only AIH\           AIH & PBC\              
                                                                  (n = 3783, 92.6%)   (n = 302, 7.4%)         
  --------------------------------------------------------------- ------------------- ----------------- ----- ------
  **Gender**                                                                                                  

   Male                                                           558                 14.8              34    11.3

   Female                                                         3225                85.2              268   88.7

  **Age (years)**                                                                                             

   0--9                                                           12                  0.3               0     0.0

   10--19                                                         60                  1.6               0     0.0

   20--29                                                         150                 4.0               6     2.0

   30--39                                                         304                 8.0               24    7.9

   40--49                                                         643                 17.0              75    24.8

   50--59                                                         1123                29.7              94    31.1

   60--69                                                         921                 24.3              74    24.5

   70--79                                                         490                 13.0              24    7.9

   80+                                                            80                  2.1               5     1.7

   Average                                                        54.9                54.2                    

   Median (Q1, Q3)[‡](#t004fn003){ref-type="table-fn"}            56 (47, 65)         54 (46, 62)             

  **Fatality in 2009--2013**                                                                                  

  Gender                                                                                                      

   Male                                                           45                  8.1               3     8.8

   Female                                                         197                 6.1               26    9.7

  Age (years)                                                                                                 

   Average                                                        64.5                59.9                    

   Median (Q1, Q3)[‡](#t004fn003){ref-type="table-fn"}            67 (56, 75)         61 (55, 67)             

  **Complications**                                                                                           

  Ascites[\*](#t004fn001){ref-type="table-fn"}                    65                  1.7               12    4.0

   Prescription of spironolactone                                 266                 7.0               45    14.9

   Prescription of furosemide                                     571                 15.1              62    20.5

  Variceal bleeding[\*](#t004fn001){ref-type="table-fn"}          59                  1.6               19    6.3

   Endoscopic intervention                                        75                  2.0               21    7.0

   TIPS[†](#t004fn002){ref-type="table-fn"}                       2                   0.1               0     0.0

   Prescription of vasoactive agents                              100                 2.6               15    5.0

   Prescription of propranolol                                    225                 5.9               32    10.6

  Hepatic encephalopathy[\*](#t004fn001){ref-type="table-fn"}     94                  2.5               6     2.0

   Prescription of lactulose                                      552                 14.6              50    16.6

  Liver cirrhosis[\*](#t004fn001){ref-type="table-fn"}            1268                33.5              101   33.4

  Hepatocellular carcinoma[\*](#t004fn001){ref-type="table-fn"}   45                  1.2               4     1.3

   Liver resection                                                5                   0.1               0     0.0

   Local ablation                                                 11                  0.3               0     0.0

   Transarterial chemoembolization                                29                  0.8               1     0.3

  Liver transplantation[\*](#t004fn001){ref-type="table-fn"}      50                  1.3               7     2.3

  **Comorbidities**                                                                                           

  Thyroid disease                                                                                             

   Hypothyroidism                                                 140                 3.7               8     2.6

   Hyperthyroidism                                                44                  1.2               8     2.6

   Thyroiditis                                                    48                  1.3               5     1.7

   Prescription of thyroid hormone                                149                 3.9               19    6.3

   Prescription of anti-thyroid drugs                             15                  0.4               1     0.3

  Autoimmune disease                                                                                          

   Systemic lupus erythematosus                                   85                  2.2               9     3.0

   Systemic sclerosis                                             12                  0.3               5     1.7

   Rheumatoid arthritis                                           17                  0.4               1     0.3

  Dyslipidemia                                                    471                 12.5              54    17.9

   Prescription of statin                                         593                 15.7              90    29.8

  Osteoporosis                                                    12                  0.3               2     0.7

   Prescription of bisphosphonate                                 166                 4.4               13    4.3
  ------------------------------------------------------------------------------------------------------------------

\*Complications or comorbidities were identified with ICD-10 codes verified by physicians.

^†^TIPS denotes transjugular intrahepatic portosystemic shunt surgery.

^‡^Q denotes quartile.

Economic burden of AIH in Korea {#sec015}
-------------------------------

The total national direct medical cost for AIH increased from 1,872,872 USD in 2009 to 3,654,099 USD in 2013 ([Table 5](#pone.0182391.t005){ref-type="table"}). The annual direct medical cost per capita was 1,174 USD in 2013. Direct medical cost per capita was higher in men compared to that in women. All national medical costs for health services not covered by the NHI were excluded.

10.1371/journal.pone.0182391.t005

###### Annual direct medical cost[\*](#t005fn001){ref-type="table-fn"} of patients with AIH in 2013.
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  Age      Male   Female                               
  -------- ------ --------- ------- ------ ----------- -------
  \<20     14     15,859    1,133   18     35,897      1,994
  20--29   24     17,180    716     57     61,167      1,073
  30--39   27     41,899    1,552   152    154,718     1,994
  40--49   60     44,017    734     405    394,693     975
  50--59   93     230,780   2,482   825    884,611     1,072
  60--69   99     169,394   1,711   734    854,979     1,165
  70--79   79     99,628    1,261   435    520,100     1,196
  80+      16     7,110     444     75     122,066     1,628
  Total    412    625,868   1,519   2701   3,028,231   1,121

\*Direct medical cost includes only cost reimbursed by the National Health Insurance.

^†^1 USD = 1150 KRW

Discussion {#sec016}
==========

The present study is the first nationwide epidemiology report on AIH in South Korea. The average age- adjusted prevalence of AIH between 2009 and 2013 was 4.8 per 100,000 persons, and the gender-adjusted prevalence rates were 8.4/100,000 for females and 1.3/100,000 for males. The average age-adjusted incidence of AIH was 1.1/100,000/year, and the gender- adjusted prevalence rates were 1.8/100,000/year for females and 0.3/100,000/year for males.

Compared to other populations, the incidence and prevalence of AIH in South Korea found in this study was quite low. The incidence and prevalence rates of AIH vary widely across different populations ([Table 6](#pone.0182391.t006){ref-type="table"}).\[[@pone.0182391.ref001]--[@pone.0182391.ref014], [@pone.0182391.ref016]\] The prevalence was highest in an Alaskan native population (42.9/100,000), modest in European and New Zealand populations (mainly Caucasians, 10.7--24.5/100,000), and low in populations from Singapore and Brunei (4--5.6/100,000).\[[@pone.0182391.ref001]--[@pone.0182391.ref006], [@pone.0182391.ref009], [@pone.0182391.ref010]\] The annual incidence rate was low in Taiwan and Israel (0.52--0.67/100,000) and relatively high in Europe (0.85-3/100,000).\[[@pone.0182391.ref001], [@pone.0182391.ref004], [@pone.0182391.ref008]--[@pone.0182391.ref010], [@pone.0182391.ref012]--[@pone.0182391.ref014]\] Recently, a Japanese study reported a high prevalence and incidence of AIH (23.4/100,000 and 2.23/100,000/year, respectively).\[[@pone.0182391.ref011]\]

10.1371/journal.pone.0182391.t006

###### Prevalence and incidence of AIH.

![](pone.0182391.t006){#pone.0182391.t006g}

                                                 Year   Region                     Cases (no)                        Prevalence period   Prevalence/100,000             Incidence period   Annual incidence/100,000    Diagnostic method
  ---------------------------------------------- ------ -------------------------- --------------------------------- ------------------- ------------------------------ ------------------ --------------------------- ---------------------------------------------
  Boberg KM et al.\[[@pone.0182391.ref001]\]     1998   Norway (Oslo)              25                                1995                16.9                           1986--1995         1.9                         Original criteria\[[@pone.0182391.ref016]\]
  Lee YM et al.\[[@pone.0182391.ref002]\]        2001   Singapore                  24 (11 definite/13 probable)      1990--1996          4                              NA                 NA                          Original criteria
  Hurlburt KJ et al.\[[@pone.0182391.ref003]\]   2002   Alaska natives             49 (42 definite/7 probable)       1983--2000          42.9                           NA                 NA                          Revised criteria
  Koay LB et al.\[[@pone.0182391.ref012]\]       2006   Taiwan                     48 (29 definite/19 probable)      NA                  NA                             2000--2004         0.52                        Revised criteria
  Wally S et al.\[[@pone.0182391.ref013]\]       2007   England (West Suffolk)     6                                 NA                  NA                             2003--2004         3                           Clinical diagnosis
  Werner M et al.\[[@pone.0182391.ref004]\]      2008   Sweden                     110                               2003                10.7                           1990--2003         0.85                        Clinical diagnosis
  Primo J et al.\[[@pone.0182391.ref014]\]       2009   Spain (Valencia)           19                                NA                  NA                             2003               1.07                        Revised criteria
  Jalihal A et al.\[[@pone.0182391.ref005]\]     2009   Brunei                     19                                2008                5.6                            NA                 NA                          Revised criteria
  Ngu JH et al.\[[@pone.0182391.ref006]\]        2010   New Zealand (Canterbury)   138 (123 definite/ 15 probable)   2008                24.5 (Age-standardized 18.9)   2008               2.0 (Age-standardized1.7)   Revised/simplified criteria
  Haider AS et al.\[[@pone.0182391.ref007]\]     2010   Australia (Canberra)       42                                Unknown             8                              NA                 NA                          Revised criteria
  Delgado JS et al.\[[@pone.0182391.ref008]\]    2013   Israel                     100 (73 definite/27 probable)     1995--2010          11.0                           1995--2010         0.67                        Simplified criteria
  van Gerven et al.\[[@pone.0182391.ref009]\]    2014   Netherland (Amsterdam)     146                               1967--2011          18.3                           2000--2010         1.1                         Revised/simplified criteria
  Gronbaek L et al.\[[@pone.0182391.ref010]\]    2014   Denmark                    1,721                             2012                23.9                           1994--2012         1.68                        Clinical diagnosis
  Yoshizawa K et al.\[[@pone.0182391.ref011]\]   2016   Japan (Ueda)               48                                2014                23.4                           2004--2014         2.23                        Revised criteria
  Kim et al                                      2017   Korea                      4,085                             2009--2013          4.8                            2011--2013         1.1                         Clinical diagnosis

The wide variation seems attributable to differences between study populations as well as in the identification and definition of cases. In this population-based epidemiological study of AIH in South Korea, cases were identified by ICD-10 code and RID registry information, which are nationwide, comprehensive data sets. The government-run RID registry program is a system for copayment where if a physician diagnoses a patient with AIH based on NHI-provided criteria and enters the ICD code-10 of K75.4, he or she can register the patient for the RID program, which would then provide copayment reduction for the patient. Therefore, we believe the identification of our patients with AIH is reliable.

In other Asian countries, such as Japan and Hong Kong, the frequency of AIH is less than 5% of all chronic active hepatitis cases, whereas in Western Europe and North America, AIH comprises about 20% of these cases.\[[@pone.0182391.ref017]\] In South Korea, autoimmune liver diseases including AIH have been reported to account for 1% of chronic liver diseases.\[[@pone.0182391.ref018]\]

The presence of complications or comorbidities was primarily investigated through ICD-10 codes. However, we also examined whether a patient got therapeutic procedures or any relevant medications as ICD-10 codes for complications such as ascites, variceal bleeding or hepatic encephalopathy are often not entered into the claims data system. For example, according to the ICD-10 codes, ascites was present in 3.9% of patients with AIH. However, spironolactone, a drug of choice in the initial treatment of ascites, was prescribed in 11.6%. This range of prevalence of decompensated cirrhosis reflects the limitation of claims data. Hepatocellular carcinoma was diagnosed in 0.8% (31/4,085) of patients. Previously reported frequencies of hepatocellular carcinoma in patients with AIH are 1.1% (8/730 patients),\[[@pone.0182391.ref009]\] 1.9% (6/322 patients),\[[@pone.0182391.ref019]\] 3.6% (7/193 patients),\[[@pone.0182391.ref020]\] 4.0% (10/248 patients)\[[@pone.0182391.ref021]\] and 6.2% (15/243 patients).\[[@pone.0182391.ref022]\] Hepatocellular carcinoma frequency mainly depends on the presence of cirrhosis and the duration of the disease.\[[@pone.0182391.ref023]\] Liver transplantation was performed in 1.1% of our patients. As we could only identify cases of AIH diagnosed with hepatocellular carcinoma or followed by liver transplantation within the 5 year study period, these values may be underreported due to the relatively short follow up period.

A previous nationwide Korean study reported autoimmune thyroiditis as the most common concurrent autoimmune disease, followed by systemic lupus erythematosus.\[[@pone.0182391.ref024]\] In this study, we could not confirm the diagnosis of autoimmune thyroiditis; however, thyroid hormone was prescribed in 3.6% of patients with AIH. Therefore, it is conceivable that autoimmune thyroiditis was present in 3.6% or less. Out of the 4,085 patients, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis was present in 1.6%, 0.2% and 0.2% of patients, respectively. These were lower compared to previous reports.\[[@pone.0182391.ref025]\] Corticosteroid or azathioprine was given to approximately 40% of patients, respectively. It seemed to be low; however, analysis was performed for prevalent cases. Prevalent AIH cases in year 2013 possibly include patients who were on remission after treatment for AIH. Previous study also reported that 25% of newly diagnosed patients were not treated.\[[@pone.0182391.ref024]\]

The strength of the present study is its population-based design. The NHI claims data covers \> 95% of the entire Korean population. However, we had some limitations. First, this study was based on insurance claims data. The Korean NHI claims data includes all records of surgery, procedures, tests and medications; however, detailed clinical information such as exact results of tests could not be obtained for each individual patient. Therefore, we were not able to confirm which diagnostic criteria were used, nor could we evaluate clinical features and treatment responses. Some disease codes not responsible for the medical billing could also have been underreported. To complement this limitation, we investigated the prescription rate of concurrent medication or related procedures for complications or comorbidities. Second, the incidence and prevalence of AIH may be underestimated as the actual registration rate of AIH for RID program is not known yet. However, the disease code for AIH (K75.4) is the primary code responsible for the payment and financial benefit and most healthcare institutions and doctors are well aware of the RID program and try to register patients in the program as it offers financial benefits for patients. Third, medical costs may be underestimated because records of some uninsured health services could not be collected. Lastly, the RID registry system has been established since 2009 and this study collected information during a 5 year period, which is limited when evaluating long-term prognoses such as mortality and HCC risk.

In conclusion, this is the first nationwide study on the incidence, prevalence, complications, comorbidities and medical cost of AIH in South Korea. In Korea, the incidence and prevalence were low compared to those of other Western countries with considerable disease burden.

AIH

:   autoimmune hepatitis

ICD

:   International Classification of Disease

NHI

:   National Health Insurance

PBC

:   primary biliary cirrhosis

RID

:   rare intractable disease
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